SCHEMBL2817262

SCHEMBL2817262

CC(C)(C)OC(=O)N1CC(N(Cc2ccccc2)C(=O)OCC(Cl)(Cl)Cl)CC1C(=O)N1CCN(c2ccccc2C#N)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.40
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
MC4R P32245 1/20 0.37
CTSL P07711 2/20 0.36
CTSS P25774 2/20 0.36
TGM2 P21980 1/20 0.36
GRM5 P41594 1/20 0.35
CHRM4 P08173 1/20 0.35
PGR P06401 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
GPR119 Q8TDV5 1/20 0.35
DPP4 P27487 1/20 0.34
NR1H2 P55055 2/20 0.34
NR1H3 Q13133 2/20 0.34
PARP1 P09874 1/20 0.34
UCHL1 P09936 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13841898 1.00 HSD11B1 (0.40) HSD11B1JAK2JAK1MC4RCTSL
SCHEMBL2817891 0.88 HTR2A (0.39) PGRDPP4
SCHEMBL13841903 0.88 GRM5 (0.38) HSD11B1MC4RCTSLCTSSGRM5
SCHEMBL2820725 0.87 GPR119 (0.40) MC4RTGM2GRM5GPR119DPP4
SCHEMBL13841899 0.82 HSD11B1 (0.45) HSD11B1JAK2JAK1NR1H2NR1H3
SCHEMBL2820222 0.82 HSD11B1 (0.45) HSD11B1JAK2JAK1NR1H2NR1H3
SCHEMBL13841902 0.81 HDAC2 (0.42) MC4RGRM5CHRM4DPP4
SCHEMBL2818780 0.81 HDAC2 (0.42) MC4RGRM5CHRM4DPP4
SCHEMBL2817569 0.80 HSD11B1 (0.43) HSD11B1JAK2JAK1NR1H2NR1H3
SCHEMBL13841900 0.80 HSD11B1 (0.43) HSD11B1JAK2JAK1NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2155672-B1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-10-27 EP disclosed
EP-2155672-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-02-24 EP disclosed
US-7528136-B2 for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD); 2-{4-[(2S,4S)-1-benzyl-4-(2,4-difluoro-benzylamino)-pyrrolidine-2-carbonyl]-piperazin-1-yl}-benzonitrile HOFFMANN-LA ROCHE INC. (US) 2009-05-05 US disclosed
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-11 US disclosed
WO-2008148689-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306086-A1 PROLINAMIDE DERIVATIVES AS NK3 ANTAGONISTS SLC6A3, OPRL1, OPRK1 HSD11B1 2349/4885JAK2 703/4885JAK1 1220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.